Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yoshiko Abe.
European Journal of Pharmacology | 2000
Yoshiko Abe; Kouji Inagaki; Akihiko Fujiwara; Kiyoshi Kuriyama
The studies were carried out to elucidate the effect of a novel cyclic peptide, SEK-1005 (C(45)H(70)N(8)O(13)), on wound healing. SEK-1005 (4-10 microg/wound) applied topically significantly accelerated the healing of a full-thickness wound on the dorsal skin of a rat. In a healing-impaired mouse, the peptide (2-10 microg/wound) had more potent activity, exerting an effect comparable to that of basic fibroblast growth factor (FGF). However, SEK-1005 (0.1-100 ng/ml) scarcely promoted the proliferation of cultured fibroblasts (NIH3T3 cells) while basic FGF (0.2-5 ng/ml) showed marked mitogenic activity. SEK-1005 (2-10 microg/wound) significantly increased the topical production of transforming growth factor (TGF)-beta1, a cytokine that is known to accelerate wound healing. This activity was closely correlated with the wound-repairing effect. From the above, SEK-1005 can be considered as a new type of wound healing agent with potent TGF-beta1-inducing activity.
European Journal of Pharmacology | 2000
Kiyoshi Kuriyama; Akihiko Fujiwara; Kouji Inagaki; Yoshiko Abe
The pharmacological activity of a novel cyclic peptide (SEK-1005: C(45)H(70)N(8)0(13)) isolated from Streptomyces nobilis was studied in rats during the development of inflammation. SEK-1005 (0.1-0.5 mg/kg, i.p.) suppressed the passive Arthus reaction and the carrageenin-induced oedema. A steroidal anti-inflammatory drug, prednisolone (10 mg/kg, i.p.), also was effective on both inflammations. However, indomethacin (5 mg/kg, i.p.), a cyclooxygenase inhibitor, was less effective on the passive Arthus reaction. Also interesting was that the SEK-1005 effect showed its maximum level after a 24-h lag period and that its effect, as well as the prednisolone effect, was reduced by the treatment with a protein synthesis inhibitor, cycloheximide. SEK-1005 and prednisolone also showed marked protection against the adjuvant-induced arthritis, but failed to prevent the tuberculin response. These findings indicate that SEK-1005 is a new type of non-steroidal anti-inflammatory agent with an action similar to that of prednisolone.
Archive | 2001
Yoshiko Abe; Koji Inagaki; Koji Kobayashi; Kiyoshi Kuriyama; 幸司 小林; 澄 栗山; 孝司 稲垣; 佳子 阿部
Archive | 2002
Koji Inagaki; Yoshiko Abe; Kiyoshi Kuriyama
Archive | 1995
Akihiko Fujiwara; Kiyoshi Kuriyama; Yoshiko Abe; Koji Inagaki
Journal of Clinical Laboratory Analysis | 2002
Kikumi Suzuki; Takatoshi Koyama; Shizuko Kobayashi; Koji Kobayashi; Koji Inagaki; Yoshiko Abe; Kiyoshi Kuriyama; Kiyoko Shiba
Archive | 1994
Akihiko Fujiwara; Kiyoshi Kuriyama; Yoshiko Abe; Koji Inagaki
Archive | 2008
Yoshiko Abe; 阿部佳子; Eriko Kusaka; 日下絵里子; Koji Inagaki; 稲垣孝司; Junichi Kondo; 近藤純一; Kazuo Shinmura; 新村和夫; Hiroshi Uyama; 宇山浩; Kazuo Maeshima; 前島一夫
Journal of Toxicological Sciences | 2006
Kohji Kobayashi; Yoshiko Abe; Kiyoshi Kuriyama
Archive | 2004
Shinichiro Kitahara; Kazuo Shinmura; Yoshiko Abe; Kiyoshi Kuriyama